On March 1, 2019, Spectrum Pharmaceuticals reported that it completed the sale of our seven then-commercialized drugs, including FUSILEV, KHAPZORY, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA (the "Commercial Product Portfolio") to Acrotech Biopharma LLC ("Acrotech") (the "Commercial Product Portfolio Transaction") (Press release, Spectrum Pharmaceuticals, MAR 1, 2019, View Source [SID1234538580]). Upon closing Spectrum Pharmaceuticals received $158.8 million in an upfront cash payment (of which $4 million is held in escrow). Spectrum Pharmaceuticals is also entitled to receive up to an aggregate of $140 million upon Acrotech’s achievement of certain regulatory (totaling $40 million) and sales-based milestones (totaling $100 million) relating to the Commercial Product Portfolio.
These Condensed Consolidated Financial Statements are recast for all periods presented to reflect the sale of the assets and liabilities associated with their Commercial Product Portfolio, as well as the corresponding revenue-deriving activities and allocable expenses of this commercial business within "discontinued operations" – see Note 11. Spectrum have presented their face financial statements in general conformity with our historical format, even where presented values are $-0- within continuing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!